A commercial semi-quantitative kit (Trace) for urinary porphobilinogen (PBG) in which urine is pre-treated with ion-exchange resin and the colour of the Ehrlich-PBG adduct matched against a set of surrogate standards was compared with qualitative screening methods (Watson-Schwartz) in common use. Twenty samples in which PBG had been quantitated were blindly tested by both methods in each of 13 typical user laboratories. For urine samples with raised PBG, 123 out of 129 results were positive when tested with the Trace kit. Using qualitative tests routinely in use in the various laboratories only 45 out of 119 results were unequivocally positive. Sixteen out of 91 results for pigmented urine samples with normal PBG were reported as positive using qualitative screening tests, but only one using the Trace kit. Therefore, the Trace method is far more sensitive and specific than the qualitative screening tests. It is recommended that Watson-Schwartz-type screening tests should be abandoned and, ideally, all urine samples analysed by quantitative methods. However, the Trace method is a convenient alternative which is adequate for the initial screening of symptomatic patients.
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The acute porphyrias (i.e., acute intermittent porphyria, variegate porphyria, hereditary coproporphyria and plumboporphyria) are rare inherited defects of haem biosynthesis, in which sufferers experience life-threatening neuropsychiatric attacks. With the exception of the exceedingly rare plumboporphyria, the hallmark of the acute porphyric attack is increased excretion of the monopyrrole porphobilinogen (PBG) in the urine. Therefore, examination of urine for excess PBG is an essential investigation in patients with suspected acute porphyria.
The 'gold standard' for the estimation of urinary PBG is the method of Mauzerall and Granick, I in which interfering substances are removed by chromatography on an anionexchange column, before reaction of PBG with Ehrlich's reagent (4-dimethylaminobenzaldehyde in acid solution) to form a red-pink chromogen which is measured photometrically.
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This method is reliable and available commercially, but is slow and labour intensive and therefore unattractive to most clinical chemistry laboratories. Instead, most laboratories rely upon simple qualitative 'screening tests' (e.g., the Watson-Schwartz test") in which urine is reacted directly with Ehrlich's reagent. To improve the reliability of the test most of these methods employ extraction of the final reaction mixture with an organic solvent in an attempt to remove interfering chrornogens. There is now a considerable body of evidence:' 7 that these methods are unreliable in routine usc, with many false positives and false negatives. Although performance may be improved by following a good validated protocol and participating in external quality assessment schemes to improve familiarity with positives," there is clearly a need for a simple alternative test so that this important investigation may be reliably performed in the laboratory of every district general hospital responsible for acute medical and surgical patients. The Mauzerall and Granick method has been modified, in attempts to produce an alternative which is acceptable for screening purposes.
Buttery et al" avoided the use of columns by employing batch-wise treatment of urine with resin, and visually compared the final colour with that of a surrogate standard. Blake et al. I D eliminated the need for centrifugation steps by using resin-filled syringes with detachable filters and compared the final colour with a range of artificial standards. These modifications reduced the time taken to perform the test to approximately 10min and produced a semi-quantitative result. This test is now available commercially in kit form and we undertook an independent evaluation on a multi-centre basis, comparing the performance of the method with that of commonly used qualitative screening tests.
MATERIALS AND METHODS

Design of the study
Thirteen laboratories were recruited to participate in the study. They represented a range of laboratories, both teaching and non-teaching in the UK. Four distributions were sent out by first class post at weekly intervals. Each distribution consisted of 10 samples and laboratories were asked to test five of the urines using the Trace PBG kit and the other five by their routine qualitative screening method. They were requested to record the dates of receipt and analysis of the specimens, to perform the tests within 48 h and to refrigerate the samples (at approximately 4"C) whilst awaiting analysis. The identities of the specimens were unknown to participants and most urine specimens in the two sets of samples of each distribution were unrelated. The compositions of the samples were verified by quantitation of PBG prior to despatch. Stability was confirmed by PBG measurement of a duplicate set of samples stored in the dark at room temperature for 2 days (to mimic postal conditions), then for a further 3 and 10 days at 4"C (to simulate storage in participants' laboratories).
Samples
Three types of samples were used for the study: urine specimens from patients with acute intermittent porphyria (AlP), normal urine specimens to which had been added varying amounts of PBG (obtained from Sigma Chemical Co. Ltd, Poole, Dorset, UK) and abnormally Screening test for acute porphyria 727
pigmented urine specimens with normal PBG concentrations.
PBG measurement PBG was measured by the method of Mauzerall and GranickI using commercial ion-exchange columns obtained from Bio-Rad Laboratories Ltd (Hemel Hempstead, Herts, UK).
Qualitative screening tests The routine qualitative screening tests used by all laboratories were based on the direct reaction of untreated urine with Ehrlich's reagent. There were minor variations in details of the methods used but six laboratories quoted the source of their method as Elder GH, Smith SG, Smyth SJ. 
The Trace PBG method
Each laboratory was supplied with one Trace PBG kit (obtained from Alpha Laboratories Ltd, Eastleigh, Hampshire, UK). Each kit contained sufficient reagents, syringes, filters and reaction tubes for 20 tests, together with a set of three artificial standards and full instructions.
The pH of the urine was first checked and if below 6 was adjusted to between 6 and 8 by the addition of aqueous ammonia (6%). Urine (I mL) and an air bubble were aspirated into a syringe containing anion-exchange resin, the filter attached then mixed gently for 10 sand the urine expelled to waste. The filter was then removed, and distilled or deionized water (I mL) and an air bubble were aspirated. The filter was re-attached, and the contents were mixed gently for lOs then expelled to waste. The filter was again removed, elution reagent (I mL) and an air bubble were aspirated, and the filter was reattached and the contents mixed for 10 s. The contents of the syringe were then expelled into a Where the reported result fell between two categories it was shared between the two; for example a result reported as ND/ + was recorded as 0·5 for the ND and 0·5 for the + categories.
RESULTS
Forty-five of the 52 sets of samples were received by the participating laboratories within 2 days of despatch, and 47 sets were tested within 5 days. The stability experiment (data not shown)
Ann Clin Biochem 1998: 35 confirmed that only minimal losses occurred over this period; the PBG concentrations measured on day 5 were used as target values. Table I shows the total number of results falling into each category for each of the screening methods, compared with the quantitative PBG results arranged into the following groupings: 0-25Ilmol/L, 2550 fLmol/L, 50-100pmol/L and > 100fLmol/L. For urine samples with raised PBG (greater than 25Ilmol/L), ins (from patients with congenital erythropoietic porphyria. lead poisoning. or acute intermittent porphyria in which the POG had hcen allowed to decompose). excess bilirubin (a patient with alcoholic hepatitis), or sufficient added blood or beetroot juice to impart a faint red colour, Therefore. these urine samples were abnormally pigmented but contained normal amounts of PHG. Only one positive result ( + category) was obtained using the Trace kit. hut many false positives were obtained with the qualitative screening methods. Unfortunately, we were unable to obtain suitable specimens with which to investigate possible interference by urobilinogen (the manufacturer claims that there is no interference). Figure I shows the results obtained for two urine samples with virtually identical POG concentrations (69 and 6X [Imol/L) hut widely differing creatinine concentrations (3,3 and 19.1 rnmol.L). The distribution of results is very different for these two urine samples whichever method is used. sensitivity decreasing as urine becomes more concentrated. Therefore. the manufacturer's claim that the detection limit of the Trace method is independent of urine colour was not substantiated. Table 3 shows the tota1 numhcr of results falling into each category for each of the screening methods. compared with the quantitative results expressed as a ratio to creatinine concentration. The urine samples were grouped into three categories according to the measured PHG:creatinine ratios: normal (less than 1·5 [Imol mmol). intermediate examination of urine for excess PBG is the key investigation in patients with suspected acute porphyria.
The purpose of a screening test is to detect all urine specimens with clinically significant increases in PBG, which can then be analysed by quantitative methods. Clearly, the Watson-Schwartz-type screening tests in common use are unsuitable for this purpose because a large proportion of laboratories obtained negative results for urine samples with significantly elevated PBG concentrations. However, the higher the PBG concentration the greater the likelihood of a positive result, but even for a urine from a porphyric patient with a PBG concentration at 10 times the upper reference limit, seven out of the 13 laboratories reported a negative screening test. Therefore, not only is this test too insensitive to detect small elevations in PBG encountered during remission, but there is also a danger of missing a porphyric crisis. The sensitivity of the Trace method is superior to the qualitative screening tests with a much lower risk of obtaining false negatives. Most participants commented that the inclusion of a range of standards in the kit considerably helped interpretation of the result.
The question arises as to what is a suitable detection limit. This partly depends upon whether the purpose of the test is to detect symptomatic or latent cases, but there are other considerations. First, the upper limit for PBG excretion is usually taken as approximately 10 J.lmol/24h; the actual concentration depending upon 24 h urine volume. However, most tests are performed on random urine samples with even wider variations in PBG concentration. To overcome this problem, Blake et u/. 1lI have recommended that quantitative results should be expressed as a ratio to creatinine and propose an upper reference limit of 1·5/lmol PBG/mmol creatinine. Thus, a 10-fold variation in urine concentration (with creatinine ranging from 3 to 30 rnrnol/L) at this cut-off level could easily result in PBG concentrations ranging from 4·5 to 451Imol/L. The detection limit of 25 /lmol/L used in the Trace method is a reasonable compromise and was used in this study to evaluate the relative performance of the two methods. Second, the detection limit varies with background colour of urine (Fig. I) . Urine samples from acutely ill patients are likely to be concentrated owing to vomiting and reduced fluid intake. A possible solution would be to dilute all urine samples to a constant creatinine concentration (e.g., 4 rnmol/L). However, this would lengthen the procedure and the upper reference limit would become 6 /lmol/L, which is below the detection limit of the method. Furthermore, erroneous creatinine values may be obtained in acutely ill patients owing to interference (caused by ketones) in the creatinine determination if a Jaffe method is used. In the present study all urine samples with PBG:creatinine ratios greater than four times the upper reference limit gave positive results when tested with the Trace kit. However, when a urine with a PBG:creatinine ratio of 37 times the upper reference limit was tested by the qualitative screening tests four out of the 13 laboratories reported a negative result. PBG excretion rates of greater than 10 times the upper reference limit are compatible with acute porphyria as the cause of any symptoms and our data shows that the Trace method should have no difficulty detecting such an increase, whereas the qualitative screening tests would be likely to give a negative result. Unfortunately, neither method can be relied upon to detect the small increases in PBG which may be found during the latent phase in adults or in clinical remission, and quantitation using the Mauzerall and Granick I method is recommended in these circumstances.
The ideal screening test should also be highly specific, i.e., there should be few false positives. The qualitative screening tests gave many false positives for abnormally pigmented urine samples, due to interference by excess porphyrins or added pigments such as beetroot juice. The latter was included because some patients absorb and excrete significant amounts of plant pigments and there has been one report of beetroot juice being added surreptitiously by a patient to his Screening test for acute porphyria 731 own urine. I I The Trace method is relatively free from positive interference by pigments. A small number of false positives were obtained for normal urine samples by the Trace method but all of these were in the lowest (+ ) category and so would be unlikely to be confused with values usually encountered in patients with an attack of acute porphyria. However, even a minimally elevated PSG excretion rate requires further investigation. The semi-quantitative results obtained with the Trace method, although correlating poorly with the quantitative results, permit a rough guide to the magnitude of the increase in PBG and, hence, the likelihood of the patient's symptoms being due to porphyria. This study has confirmed previous reports':" that the Watson-Schwartz test, as performed in most laboratories, is unreliable. It is our view that the continued use of this test cannot be justified. Ideally, PBG should be quantitated in all urine samples by using the Mauzerall and Granick column method.' If a screening test must be used, then the Trace PBG kit performs better than qualitative screening tests and appears adequate for the initial investigation of patients with symptoms suggestive of an acute porphyria attack. However, this method is unsuitable for the investigation of patients during the latent phase or in clinical remission. 
